Bribery and Corruption risks in the Healthcare & Life Sciences sector

Corruption issues are one of the most damaging financial crime risks to which Healthcare & Life Sciences businesses are exposed. The enforcement risk is very real - the SFO considers that the pharmaceutical and medical devices sectors are particularly prone to corruption. The enforcement risks are multi-jurisdictional and the authorities closely co-operate to share intelligence and to direct investigations.

This session identifies the key corruption enforcement risks and themes, relevant to Healthcare & Life Sciences, that have emerged over the last twelve months and steps companies should take to mitigate those risks. The session also provides an update on the current enforcement landscape in the UK and the US.

To view the slides from the session please click here

To view the webinar please click here